AIMT - Aimmune Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Aimmune Therapeutics, Inc.

8000 Marina Boulevard
Suite 300
Brisbane, CA 94005
United States
650-614-5220
http://www.aimmune.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees258

Key Executives

NameTitlePayExercisedYear Born
Dr. Jayson Donald Alexander DallasPres, CEO & Director859.79kN/A1968
Mr. Eric H. BjerkholtChief Financial Officer589.17kN/A1960
Mr. Douglas T. SheehyGen. Counsel & Sec.539.88k249.28k1967
Dr. Stephen George DillySpecial Advisor308.93k8.57M1960
Dr. Daniel C. AdelmanChief Medical Officer611.93k1.05M1957
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.

Corporate Governance

Aimmune Therapeutics, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.